logo

For the Inventor, By the Inventor

Chapel Hill, NC, United States of America

Asklepios Biopharmaceutical, Inc.


USPTO Granted Patents = 12


Forward Citations = 77

Loading Chart...
Loading Chart...

13 inventors (with patents filed for the assignee):

goldMedal Richard Jude Samulski (4 out of 68 patents)

silverMedal Michael L Roberts (3 out of 7 patents)

bronzeMedal Gretchen M Unger (2 out of 7 patents)

4.  Vicci Korman (2 out of 2 patents)

5.  Xiao Xiao (2 out of 28 patents)

6.  Graham Whyteside (1 out of 3 patents)

7.  Ross Fraser (1 out of 3 patents)

8.  Joanna Critchley (1 out of 1 patent)

9.  Anne Braae (1 out of 2 patents)

10.  Nicolle Kippen (1 out of 2 patents)

11.  Juan Manuel Iglesias Gonzalez (1 out of 1 patent)

12.  Jorge Omar Yanez-Cuna (1 out of 2 patents)

13.  Juan Manuel Iglesias (1 out of 2 patents)


12 patents:

1. 12630595 - REGULATORY NUCLEIC ACID SEQUENCES (2026-05-19),
2. 12241115 - Methods and compositions for enriching nucleic acids (2025-03-04),
3. 12036287 - Nanoparticles comprising protein-polynucleotide complexes and for delivering protein based complexes (2024-07-16),
4. 11492618 - Expression control using a regulatable intron (2022-11-08),
5. 11414678 - Modified soluble VEGF receptor-1 genes and vectors for gene therapy (2022-08-16),
6. 11268089 - Method for the construction of specific promoters (2022-03-08),
7. 11235070 - Nanoparticles comprising protein-polynucleotide complexes and for delivering protein based complexes (2022-02-01),
8. 10385112 - Modified soluble VEGF receptor-1 genes and vectors for gene therapy (2019-08-20),
9. 9506052 - Modified factor VIII and factor IX genes (2016-11-29),
10. 8198421 - Modified factor VIII and factor IX genes and vectors for gene therapy (2012-06-12),
11. 7510867 - DNA sequences encoding dystrophin minigenes and methods of use thereof (2009-03-31),
12. 7001761 - DNA sequences comprising dystrophin minigenes and methods of use thereof (2006-02-21),
Company Overview
Asklepios Biopharmaceutical, Inc., based in Chapel Hill, North Carolina, specializes in the development of innovative gene therapies aimed at treating various genetic disorders and diseases. The company focuses on leveraging advanced biopharmaceutical technologies to create effective therapeutic solutions, emphasizing safety and efficacy in its research. With a commitment to scientific excellence, Asklepios is dedicated to transforming the landscape of medicine through its pioneering approaches in gene therapy and biopharmaceutical development.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

Asklepios Biopharmaceutical, Inc. USPTO Patent Assignee Logo
12 Patents

#7 in Chapel Hill, NC

#554 in North Carolina

#25,557 in US

#48,163 in the World

Chapel Hill, NC (US)
Chapel Hill, NC, United States of America

Asklepios Biopharmaceutical, Inc.

Forward Citations = 77

13 inventors:

goldMedal Richard Jude Samulski (4 out of 68 patents)

silverMedal Michael L Roberts (3 out of 7 patents)

bronzeMedal Gretchen M Unger (2 out of 7 patents)

4.  Vicci Korman (2 out of 2 patents)

5.  Xiao Xiao (2 out of 28 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Asklepios Biopharmaceutical, Inc.. Retrieved from https://idiyas.com/company/asklepios-biopharmaceutical

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…